Profile data is unavailable for this security.
About the company
PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
- Revenue in CAD (TTM)0.00
- Net income in CAD-3.83m
- Incorporated2021
- Employees4.00
- LocationPsyBio Therapeutics Corp4400 Sample Road; Suite138COCONUT CREEK 33073United StatesUSA
- Phone+1 (513) 449-9585
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zenith Capital Corp | 0.00 | -14.38m | 766.78k | -- | -- | -- | -- | -- | -0.0951 | -0.0951 | 0.00 | -0.1795 | 0.00 | -- | -- | -- | -200.28 | -- | -- | -- | -- | -- | -- | -- | -- | -5.18 | -- | -- | -- | -- | 19.24 | -- | -- | -- |
Psybio Therapeutics Corp | 0.00 | -3.83m | 839.95k | 4.00 | -- | -- | -- | -- | -0.0328 | -0.0328 | 0.00 | -0.018 | 0.00 | -- | -- | -- | -357.70 | -- | -- | -- | -- | -- | -- | -- | -- | -617.30 | -- | -- | -- | -- | 55.66 | -- | -- | -- |
Claritas Pharmaceuticals Inc | 0.00 | -2.60m | 949.70k | -- | -- | -- | -- | -- | -0.0845 | -0.2023 | 0.00 | 0.1257 | 0.00 | -- | -- | -- | -17.49 | -33.39 | -51.79 | -39.16 | -- | -- | -- | -- | -- | 6.86 | 0.1409 | -- | -- | -- | 119.85 | -- | -- | -- |